Axerion Therapeutics
Pioneering breakthrough therapies for Alzheimer's and spinal cord injuries through advanced neurological research.
Pioneering breakthrough therapies for Alzheimer's and spinal cord injuries through advanced neurological research.
Axerion Therapeutics is a private biotechnology company founded in 2009, with a focus on developing innovative treatments for neurological diseases and injuries. The company's slogan "Pioneering breakthrough therapies for Alzheimer's and spinal cord injuries through advanced neurological research" reflects its dedication to addressing substantial unmet medical needs. Axerion's specialized technology platforms include inhibitors of ß-amyloid (Aß) oligomers binding to Prion Proteins (PrP) on neuron surfaces for Alzheimer’s disease, and a Nogo Receptor decoy protein designed to aid recovery of neurological function in spinal cord injuries and other conditions. The company has received a $400.00K Venture Round investment on 13 October 2011 from Connecticut Innovations, and is based in Connecticut. Axerion Therapeutics is at the forefront of pioneering treatments in the biotechnology and health care industries, leveraging research developed at Yale University to drive its advancements in the field.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $400.00K | 1 |
|
13 Oct 2011 |
| Seed Round | $750.00K | 1 |
|
05 Apr 2010 |
No recent news or press coverage available for Axerion Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
